Show simple item record

dc.contributor.authorWaning, Brendaen_US
dc.contributor.authorMaddix, Jasonen_US
dc.contributor.authorTripodis, Yorghosen_US
dc.contributor.authorLaing, Richarden_US
dc.contributor.authorLeufkens, Hubert GMen_US
dc.contributor.authorGokhale, Manjushaen_US
dc.date.accessioned2012-01-11T15:51:15Z
dc.date.available2012-01-11T15:51:15Z
dc.date.copyright2009en_US
dc.date.issued2009-12-14en_US
dc.identifier.citationWaning, Brenda, Jason Maddix, Yorghos Tripodis, Richard Laing, Hubert GM Leufkens, Manjusha Gokhale. "Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan" International Journal of Equity in Health 8:43. (2009)en_US
dc.identifier.issn1475-9276en_US
dc.identifier.urihttp://hdl.handle.net/2144/3087
dc.description.abstractBACKGROUND. A rural pharmacy initiative (RPI) designed to increase access to medicines in rural Kyrgyzstan created a network of 12 pharmacies using a revolving drug fund mechanism in 12 villages where no pharmacies previously existed. The objective of this study was to determine if the establishment of the RPI resulted in the unforeseen benefit of triggering medicine price competition in pre-existing (non-RPI) private pharmacies located in the region. METHODS. We conducted descriptive and multivariate analyses on medicine insurance claims data from Kyrgyzstan's Mandatory Health Insurance Fund for the Jumgal District of Naryn Province from October 2003 to December 2007. We compared average quarterly medicine prices in competitor pharmacies before and after the introduction of the rural pharmacy initiative in October 2004 to determine the RPI impact on price competition. RESULTS. Descriptive analyses suggest competitors reacted to RPI prices for 21 of 30 (70%) medicines. Competitor medicine prices from the quarter before RPI introduction to the end of the study period decreased for 17 of 30 (57%) medicines, increased for 4 of 30 (13%) medicines, and remained unchanged for 9 of 30 (30%) medicines. Among the 9 competitor medicines with unchanged prices, five initially decreased in price but later reverted back to baseline prices. Multivariate analyses on 19 medicines that met sample size criteria confirm these findings. Fourteen of these 19 (74%) competitor medicines changed significantly in price from the quarter before RPI introduction to the quarter after RPI introduction, with 9 of 19 (47%) decreasing in price and 5 of 19 (26%) increasing in price. CONCLUSIONS. The RPI served as a market driver, spurring competition in medicine prices in competitor pharmacies, even when they were located in different villages. Initiatives designed to increase equitable access to medicines in rural regions of developing and transitional countries should consider the potential to leverage medicine price competition as a means of achieving their goal. Evaluations of interventions to increase rural access to medicines should include impact assessment on both formal and informal pharmaceutical markets.en_US
dc.description.sponsorshipUnited States Agency for International Developmenten_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2009 Waning et al; licensee BioMed Central Ltd.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleTowards Equitable Access to Medicines for the Rural Poor: Analyses of Insurance Claims Reveal Rural Pharmacy Initiative Triggers Price Competition in Kyrgyzstanen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1475-9276-8-43en_US
dc.identifier.pubmedid20003422en_US
dc.identifier.pmcid2803474en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2009 Waning et al; licensee BioMed Central Ltd.
Except where otherwise noted, this item's license is described as Copyright 2009 Waning et al; licensee BioMed Central Ltd.